Translational Cancer Research Group, Laboratory of Pathology, University of Antwerp/University Hospital Antwerp, Edegem, Belgium.
Cancer. 2010 Jun 1;116(11 Suppl):2794-805. doi: 10.1002/cncr.25180.
Stem cells are pluripotent cells, with a large replicative potential, which perform normal physiological functions such as tissue renewal and damage repair. However, because of their long lifespan and high replicative potential, stem cells are ideal targets to accumulate multiple mutations. Therefore, they can be regarded as being responsible for the initiation of tumor formation. In the past, numerous studies have shown that the presence of an elaborate stem cell compartment within a tumor is associated with aggressive tumor cell behavior, frequent formation of metastases, resistance to therapy, and poor patient survival. From this perspective, tumors from patients with inflammatory breast cancer (IBC), an aggressive breast cancer subtype with a dismal clinical course, are most likely to be associated with stem cell biology. To date, this hypothesis is corroborated by evidence resulting from in vitro and in vivo experiments. Both gene and microRNA expression profiles highlighted several stem cell-specific signal transduction pathways that are hyperactivated in IBC. Also, these stem cell-specific signal transduction pathways seem to converge in the activation of nuclear factor-kappa B, a molecular hallmark of IBC, and induction of epithelial-to-mesenchymal transition. Recently, the latter mechanism was identified as a prerequisite for the induction of stem cell characteristics in breast cancer cells.
干细胞是多能细胞,具有较大的复制潜能,可发挥组织更新和损伤修复等正常生理功能。然而,由于其寿命长且具有较高的复制潜能,干细胞是积累多种突变的理想靶标。因此,它们可以被视为肿瘤形成的启动因素。过去的大量研究表明,肿瘤内存在精细的干细胞区室与侵袭性肿瘤细胞行为、频繁形成转移、对治疗的耐药性以及患者生存不良有关。从这个角度来看,炎性乳腺癌(IBC)患者的肿瘤最有可能与干细胞生物学有关,炎性乳腺癌是一种侵袭性乳腺癌亚型,临床预后较差。迄今为止,这一假说得到了体外和体内实验结果的证实。基因和 microRNA 表达谱均突出了几个在 IBC 中过度激活的干细胞特异性信号转导通路。此外,这些干细胞特异性信号转导通路似乎在核因子-κB 的激活中汇聚,核因子-κB 是 IBC 的分子标志,并且诱导上皮-间充质转化。最近,后一种机制被确定为诱导乳腺癌细胞中干细胞特征的前提条件。
Expert Rev Anticancer Ther. 2008-8
Semin Reprod Med. 2008-11
Climacteric. 2006-4
J Cell Biochem. 2005-6-1
Int J Dev Biol. 2011
Cancer Cell. 2006-8
Ann Surg Oncol. 2009-10-17
Cancer Res. 2006-11-15
Mol Cell Biochem. 2025-3
Int J Mol Sci. 2023-2-28
Cancers (Basel). 2021-10-23